N
NGNE icon

Natixis’s Neurogene NGNE Stock Holding History

Natixis’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
+3,721
New +$102K ﹤0.01% 984

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Natixis's NGNE Position: Q2 2026 in Review

Natixis opened a new position in Neurogene (NGNE) in Q2 2026: 3,721 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings.

112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Natixis held 3,721 shares of Neurogene worth $117K as of Q2 2026.
  • Neurogene was a new Natixis position in Q2 2026.
  • Neurogene made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #984 holding.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.